Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma

被引:61
作者
Tam, Ka Ho [1 ]
Yang, Zhen Fan [1 ]
Lau, Chi Keung [1 ]
Lam, Chi Tat [1 ]
Pang, Roberta W. C. [2 ]
Poon, Ronnie T. P. [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Surg, Ctr Canc Res, Pokfulam, Hong Kong, Peoples R China
[2] Univ Hong Kong, Queen Mary Hosp, Dept Med, Ctr Canc Res, Pokfulam, Hong Kong, Peoples R China
关键词
mTOR; p53; RAD001; HCC; Chemosensitivity; Chemoresistance; RANDOMIZED CONTROLLED-TRIAL; MAMMALIAN TARGET; CANCER; CHEMOTHERAPY; CELLS; AKT;
D O I
10.1016/j.canlet.2008.08.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study investigated the effect of mammalian target of rapamycin (mTOR) inhibition on HCC cells in vitro and in vivo, either alone or in combination with cytotoxic agents. In vitro, HCC cell lines were exposed to RAD001, an mTOR inhibitor, either alone or in combination with cisplatin. Alone, RAD001 suppressed cell proliferation in all cell lines tested, but did not induce apoptosis. RAD001 in combination with cisplatin induced a significant increase in the number of apoptotic cells, downregulated the expression of pro-survival molecules, Bcl-2, survivin and cyclinD1, and increased the cleavage of PARP, compared to RAD001 or cisplatin alone. Transfection of p53 into the Hep3B cell line increased the sensitivity of tumor cells to cisplatin. The suppression of HCC tumor growth in vivo was enhanced by RAD001 combined with cisplatin, accompanied by a significant increase in the number of apoptotic cells in tumor tissues. This study demonstrates that inhibition of mTOR suppresses tumor growth and sensitizes tumor cells to chemocytotoxic agents. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:201 / 209
页数:9
相关论文
共 27 条
  • [21] Role of p21(Waf1/Cip1/Sd1) in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells
    Sheikh, MS
    Chen, YQ
    Smith, ML
    Fornace, AJ
    [J]. ONCOGENE, 1997, 14 (15) : 1875 - 1882
  • [22] Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation
    Sieghart, Wolfgang
    Fuereder, Thorsten
    Schmid, Katharina
    Cejka, Daniel
    Werzowa, Johannes
    Wrba, Fritz
    Wang, Xiaowei
    Gruber, Diego
    Rasoul-Rockenschaub, Susanne
    Peck-Radosavlievic, Markus
    Wacheck, Volker
    [J]. TRANSPLANTATION, 2007, 83 (04) : 425 - 432
  • [23] Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
    Wendel, HG
    de Stanchina, E
    Fridman, JS
    Malina, A
    Ray, S
    Kogan, S
    Cordon-Cardo, C
    Pelletier, J
    Lowe, SW
    [J]. NATURE, 2004, 428 (6980) : 332 - 337
  • [24] WENDEL HG, 2006, CANCER RES, P7639
  • [25] Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts
    Wu, LC
    Birle, DC
    Tannock, IF
    [J]. CANCER RESEARCH, 2005, 65 (07) : 2825 - 2831
  • [26] Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis
    Yan, HJ
    Frost, P
    Shi, YJ
    Hoang, B
    Sharma, S
    Fisher, M
    Gera, J
    Lichtenstein, A
    [J]. CANCER RESEARCH, 2006, 66 (04) : 2305 - 2313
  • [27] RETRACTED: The potential role of hypoxia inducible factor 1α in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma (Retracted article. See vol. 78, pg. 3399, 2018)
    Yang, ZF
    Poon, RT
    To, J
    Ho, DW
    Fan, ST
    [J]. CANCER RESEARCH, 2004, 64 (15) : 5496 - 5503